MedTrace Logo

Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice

NCT07558707 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 7000

Last updated 2026-04-30

No results posted yet for this study

Summary

This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.

Patients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.

Conditions

  • Peptic Ulcer
  • NSAID-Induced Peptic Ulcer

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-04-30
Completion
2027-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07558707 on ClinicalTrials.gov